Kyorin Pharmaceuticals has entered into a licensing agreement with U.S.-based Merck & Co for the overactive bladder drug vibegron, hoping to expand its product lineup in the urology field. The Japanese company will obtain exclusive development and sales rights for the drug in Japan, and will pay an undisclosed upfront lump sum plus milestone payments. Merck has already completed Phase II trials with the beta 3 adrenergic receptor agonist, and Kyorin plans to initiate domestic Phase III trials. Kyorin already sells Uritos (imidafenacin) for the condition in Japan, and with this deal hopes to further strengthen its position in the urology field. (Click Here For More – Japanese Language)

“Kyorin Obtains Domestic Development And Sales Rights For Merck`s Overactive Bladder Drug Vibegron, Proceeding To P3 Trials” - mixonline.jp (7/23/2014)

Kyorin Licenses Merck’s OAB Drug Vibegron For Japan

More from Japan

More from Focus On Asia